HRMY · Harmony Biosciences Holdings Inc
United States · RS rating 61 · As of 2026-11-03
| Price | 37.02 USD |
|---|---|
| 1-day change | -2.4% |
| RS rating (overall / 1M / 3M / 12M) | 61 / 40 / 60 / 75 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 31 / 34 / 17 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -56.3% |
| Sales growth Q/Q | +1.8% |
| Distance from 52-week high | +13.6% |
| Market cap (USD) | $1.9B |